|
|
|
|
|
Cardura: profile and news
Pfizer's Norvasc reduces cardiovascular events Feb 8, 2006 Pill Pushers Feb 8, 2006 Pill Pushers 09 Feb 2006 Pfizer's Norvasc reduces cardiovascular events Feb 8, 2006 Pfizer Fourth-Quarter and Full-Year 2005 Financial Results Reflect ... Jan 19, 2006 New Data Show Hypertensive Patients Taking Norvasc-Based Regimen ... Nov 13, 2005 Cutting costs Dec 2, 2005 Label Change for Flomax Following Report of Cataract Surgery ... Nov 22, 2005 'Water pill' recommended first for blood pressure Sep 11, 2005 Karen A. Dawes Elected a Director of Repligen Corporation Sep 15, 2005 Spectrum Expands Board and Elects Pfizer's Former Marketing and ... Sep 21, 2005 Hexion Specialty Chemicals, Inc. Announces Versatics Price ... Sep 21, 2005 ASCOT Trial - Amlodipine Reduces Cardiovascular Mortality Sep 7, 2005 Prostate problems, treatments Aug 15, 2005 Pfizer Inc Second-Quarter 2005 Performance Report Jul 20, 2005 Health insurance plan promotes 'pill splitting' Jul 28, 2005 Missoula inmates upset over medications Jul 23, 2005 Living with benign prostatic hyperplasia Jun 21, 2005 Living with benign prostatic hyperplasia Jun 21, 2005 EU Commission Approves Acquisition of the German Chemical Company ... Apr 13, 2005 EC puts conditions on Bakelite sale Apr 13, 2005 Apollo's Acquistion of Bakelite Approved Apr 12, 2005 Pfizer Inc First-Quarter 2005 Performance Report Apr 19, 2005 Reaffirmation of Istin's Therapeutic Benefits to Patients After ... Mar 11, 2005 Friends of IP Mar 3, 2005 Andrx Reports Fourth Quarter 2004 and Full Year Financial Results Mar 9, 2005 Spreading the word Mar 2, 2005 Other information Indication For treatment and management of Hypertension and urinary obstruction symptoms of BPH Pharmacology Doxazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Doxazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Doxazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Doxazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Doxazosin results from a decrease in systemic vascular resistance and the parent compound Doxazosin is primarily responsible for the antihypertensive activity. Mechanism Of Action Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. Drug Category Vasodilator Agents; Antihypertensive Agents; Anticholesteremic Agents; Alpha-adrenergic Blocking Agents; ATC:C02CA04 Brand Names/Synonyms Alfadil; CARDURA; Cardenalin; Cardular; Cardura; Cardura-1; Cardura-2; Cardura-4; Carduran; Diblocin; Doxazosin mesylate; Normothen; Supressin Dosage Forms oral tablets Absorption 65% Interactions Most (98%) of plasma doxazosin is protein bound. In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin. There is no information on the effect of other highly plasma protein bound drugs on doxazosin binding. Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs. In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin. The clinical significance of this increase in doxazosin AUC is unknown. In clinical trials, doxazosin mesylate tablets have been administered to patients on a variety of concomitant medications; while no formal interaction studies have been conducted, no interactions were observed. Doxazosin mesylate tablets have been used with the following drugs or drug classes: 1. Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin). 2. Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin). 3. Antihistamines (e.g., chlorpheniramine). 4. Cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol). 5. Corticosteroids. 6. Gastrointestinal agents (e.g., antacids). 7. Hypoglycemics and endocrine drugs. 8. Sedatives and tranquilizers (e.g., diazepam). 9. Cold and flu remedies. Chemical IUPAC Name [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,5-dioxabicyclo[4.4.0]deca-6,8,10-trien-4-yl)methanone Chemical Formula C23H25N5O5 Half Life 22 hours Drug Type Approved Drug # Accession No APRD00474 CAS Registry Number 74191-85-8 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |